Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Above 50-Day Moving Average – What’s Next?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.03 and traded as high as $3.60. Oramed Pharmaceuticals shares last traded at $3.59, with a volume of 436,246 shares.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ORMP shares. Wall Street Zen raised shares of Oramed Pharmaceuticals to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Oramed Pharmaceuticals Stock Up 5.9%

The firm has a fifty day moving average price of $3.03 and a two-hundred day moving average price of $2.54. The stock has a market capitalization of $142.88 million, a P/E ratio of 2.85 and a beta of 1.19.

Oramed Pharmaceuticals Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio (DPR) is currently 19.84%.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Oramed Pharmaceuticals by 36.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,000 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 17,510 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after purchasing an additional 6,261 shares in the last quarter. Finally, BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 2.1% in the second quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company’s stock worth $6,937,000 after purchasing an additional 62,505 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.